Literature DB >> 25505062

N-linked glycosylation protects gammaretroviruses against deamination by APOBEC3 proteins.

María Carla Rosales Gerpe1, Tyler Milston Renner1, Kasandra Bélanger1, Cindy Lam1, Halil Aydin1, Marc-André Langlois2.   

Abstract

UNLABELLED: Retroviruses are pathogens with rapid infection cycles that can be a source of disease, genome instability, and tumor development in their hosts. Host intrinsic restriction factors, such as APOBEC3 (A3) proteins, are constitutively expressed and dedicated to interfering with the replication cycle of retroviruses. To survive, propagate, and persist, retroviruses must counteract these restriction factors, often by way of virus genome-encoded accessory proteins. Glycosylated Gag, also called glycosylated Pr80 Gag (gPr80), is a gammaretrovirus genome-encoded protein that inhibits the antiretroviral activity of mouse A3 (mA3). Here we show that gPr80 exerts two distinct inhibitory effects on mA3: one that antagonizes deamination-independent restriction and another one that inhibits its deaminase activity. More specifically, we find that the number of N-glycosylated residues in gPr80 inversely correlates with the sensitivity of a gammaretrovirus to deamination by mouse A3 and also, surprisingly, by human A3G. Finally, our work highlights that retroviruses which have successfully integrated into the mouse germ line generally express a gPr80 with fewer glycosylated sites than exogenous retroviruses. This observation supports the suggestion that modulation of A3 deamination intensity could be a desirable attribute for retroviruses to increase genetic diversification and avoid immune detection. Overall, we present here the first description of how gammaretroviruses employ posttranslational modification to antagonize and modulate the activity of a host genome-encoded retroviral restriction factor. IMPORTANCE: APOBEC3 proteins are host factors that have a major role in protecting humans and other mammals against retroviruses. These enzymes hinder their replication and intensely mutate their DNA, thereby inactivating viral progeny and the spread of infection. Here we describe a newly recognized way in which some retroviruses protect themselves against the mutator activity of APOBEC3 proteins. We show that gammaretroviruses expressing an accessory protein called glycosylated Gag, or gPr80, use the host's posttranslational machinery and, more specifically, N-linked glycosylation as a way to modulate their sensitivity to mutations by APOBEC3 proteins. By carefully controlling the amount of mutations caused by APOBEC3 proteins, gammaretroviruses can find a balance that helps them evolve and persist.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25505062      PMCID: PMC4338886          DOI: 10.1128/JVI.03330-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells.

Authors:  Elena Sokolskaja; Lionel Berthoux; Jeremy Luban
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

2.  Recombinant origin of the retrovirus XMRV.

Authors:  Tobias Paprotka; Krista A Delviks-Frankenberry; Oya Cingöz; Anthony Martinez; Hsing-Jien Kung; Clifford G Tepper; Wei-Shau Hu; Matthew J Fivash; John M Coffin; Vinay K Pathak
Journal:  Science       Date:  2011-05-31       Impact factor: 47.728

3.  A nonstructural gag-encoded glycoprotein precursor is necessary for efficient spreading and pathogenesis of murine leukemia viruses.

Authors:  A Corbin; A C Prats; J L Darlix; M Sitbon
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

4.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

5.  APOBEC3 inhibition of mouse mammary tumor virus infection: the role of cytidine deamination versus inhibition of reverse transcription.

Authors:  Alyssa L MacMillan; Rahul M Kohli; Susan R Ross
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

6.  Species-specific restriction of apobec3-mediated hypermutation.

Authors:  Edward P Browne; Dan R Littman
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

7.  gag-Related polyproteins of Moloney murine leukemia virus: evidence for independent synthesis of glycosylated and unglycosylated forms.

Authors:  S A Edwards; H Fan
Journal:  J Virol       Date:  1979-05       Impact factor: 5.103

8.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

Review 9.  Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment.

Authors:  Mahdis Monajemi; Claire F Woodworth; Jessica Benkaroun; Michael Grant; Mani Larijani
Journal:  Retrovirology       Date:  2012-04-30       Impact factor: 4.602

10.  Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein.

Authors:  Kasia Hrecka; Caili Hao; Magda Gierszewska; Selene K Swanson; Malgorzata Kesik-Brodacka; Smita Srivastava; Laurence Florens; Michael P Washburn; Jacek Skowronski
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

View more
  19 in total

1.  Feline Immunodeficiency Virus Vif N-Terminal Residues Selectively Counteract Feline APOBEC3s.

Authors:  Qinyong Gu; Zeli Zhang; Lucía Cano Ortiz; Ana Cláudia Franco; Dieter Häussinger; Carsten Münk
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

Review 2.  APOBECs and virus restriction.

Authors:  Reuben S Harris; Jaquelin P Dudley
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

3.  Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.

Authors:  Zeli Zhang; Qinyong Gu; Ananda Ayyappan Jaguva Vasudevan; Manimehalai Jeyaraj; Stanislaw Schmidt; Jörg Zielonka; Mario Perković; Jens-Ove Heckel; Klaus Cichutek; Dieter Häussinger; Sander H J Smits; Carsten Münk
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

4.  Intact Viral Particle Counts Measured by Flow Virometry Provide Insight into the Infectivity and Genome Packaging Efficiency of Moloney Murine Leukemia Virus.

Authors:  Tyler Milston Renner; Vera A Tang; Dylan Burger; Marc-André Langlois
Journal:  J Virol       Date:  2020-01-06       Impact factor: 5.103

5.  Murine Leukemia Virus P50 Protein Counteracts APOBEC3 by Blocking Its Packaging.

Authors:  Wenming Zhao; Charbel Akkawi; Marylène Mougel; Susan R Ross
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

6.  Deaminase-Dead Mouse APOBEC3 Is an In Vivo Retroviral Restriction Factor.

Authors:  Spyridon Stavrou; Wenming Zhao; Kristin Blouch; Susan R Ross
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

7.  Full-Length Glycosylated Gag of Murine Leukemia Virus Can Associate with the Viral Envelope as a Type I Integral Membrane Protein.

Authors:  Tyler Milston Renner; Kasandra Bélanger; Cindy Lam; María Carla Rosales Gerpe; Joanne Eileen McBane; Marc-André Langlois
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

8.  Selective Isolation of Retroviruses from Extracellular Vesicles by Intact Virion Immunoprecipitation.

Authors:  Tyler Milston Renner; Kasandra Bélanger; Marc-André Langlois
Journal:  Bio Protoc       Date:  2018-09-05

9.  Mouse APOBEC3 expression in NIH 3T3 cells mediates hypermutation of AKV murine leukemia virus.

Authors:  Stefano Boi; Morgan E Ferrell; Ming Zhao; Kim J Hasenkrug; Leonard H Evans
Journal:  Virology       Date:  2018-03-30       Impact factor: 3.616

10.  Presence of a Shared 5'-Leader Sequence in Ancestral Human and Mammalian Retroviruses and Its Transduction into Feline Leukemia Virus.

Authors:  Junna Kawasaki; Maki Kawamura; Yoshiharu Ohsato; Jumpei Ito; Kazuo Nishigaki
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.